A 28-year-old Indian male with biopsy-proven membranous nephropathy (MN) presents with nephrotic syndrome (serum albumin 2.3 g/dL, 24-hour urine protein 9.2 g, serum creatinine 1.0 mg/dL, normal complement levels). Secondary causes have been excluded. What is the drug of choice for induction of remission?

## Induction Therapy for Idiopathic Membranous Nephropathy with Nephrotic Syndrome ### Clinical Context This patient has idiopathic membranous nephropathy (IMN) with: - Nephrotic-range proteinuria (>8 g/24 h) - Preserved renal function (eGFR ~80 mL/min) - Normal complement (excludes secondary causes like lupus or infection) - Indication for immunosuppressive therapy (high proteinuria + risk of progression) ### First-Line Induction Regimen **Key Point:** Combination therapy with cyclophosphamide (or calcineurin inhibitor) + corticosteroids is the evidence-based first-line induction regimen for IMN with nephrotic syndrome. ### Two Approved Induction Protocols | Protocol | Agents | Duration | Remission Rate | |----------|--------|----------|----------------| | **Cyclophosphamide-based** | IV cyclophosphamide (0.5–1 g/m² monthly × 6) + methylprednisolone pulses + oral prednisolone | 6 months | 60–70% complete remission | | **Calcineurin Inhibitor-based** | Tacrolimus (0.05–0.1 mg/kg/day) or cyclosporine (3–5 mg/kg/day) + oral prednisolone | 12 months | 50–60% complete remission | **High-Yield:** Both regimens are superior to corticosteroids alone. Choice depends on: - **Age & fertility:** Younger patients → calcineurin inhibitor (avoids cyclophosphamide toxicity) - **Renal function:** If eGFR <30 → consider calcineurin inhibitor (cyclophosphamide less effective) - **Comorbidities:** Diabetes, infection risk → calcineurin inhibitor preferred ### Why Combination Therapy? **Clinical Pearl:** Corticosteroids alone induce remission in only 20–30% of IMN patients. The addition of a second agent (cyclophosphamide or calcineurin inhibitor) doubles remission rates and reduces relapse risk. ### Mechanism - **Cyclophosphamide** — alkylating agent; depletes B and T cells; durable remissions - **Calcineurin inhibitors** — block IL-2 signaling; reduce T-cell activation; reversible (relapse risk ~40%) - **Corticosteroids** — reduce proteinuria via anti-inflammatory effect; prevent steroid-induced complications ### When to Use Monotherapy - **Prednisolone alone** — only if patient refuses/cannot tolerate combination therapy; suboptimal outcomes - **Rituximab** — emerging option for rituximab-positive (anti-PLA~2~R antibody) IMN; not yet standard first-line in all guidelines - **Mycophenolate** — maintenance agent or alternative for intolerant patients; weaker induction efficacy [cite:KDIGO 2021 Clinical Practice Guideline for Membranous Nephropathy; Kidney Int 2021]